On May 22, 2024, ProQR Therapeutics N.V. held its annual meeting where shareholders approved several key items, including the adoption of 2023 financial accounts and appointments to the Management and Supervisory Boards. Additionally, KPMG was appointed as external auditor for 2025, with authorizations to issue and acquire shares also approved.